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What Causes Atrial
Fibrillation and Why
Do We Fail With Ablation?
Insights From Metabolic Syndrome*
Samuel J. Asirvatham, MD,†‡ Zhen Jiao, MD†
Rochester, Minnesota
A confluence of epidemics. . .. Atrial fibrillation (AF) has
been widely recognized as a modern-day disease epidemic
(1,2). Although AF ablation has been a major advance,
offering a new spectrum of treatment options for symptom-
atic patients, high recurrence rates have significantly tem-
pered initial optimism (2,3). Another alarmingly frequent
conglomerate of common disorders is the metabolic syn-
drome (MS), estimated to affect up to 21% to 24% of the
adult U.S. population (4–7).
In this issue of the Journal, Mohanty et al. (1) report their
ndings from a well-conceived, large, prospective study
1,496 consecutive patients with AF) undergoing AF abla-
ion. The investigators report a higher recurrence rate of AF
fter ablation in the patients with MS. Moreover, the
ifference in observed recurrence depended on AF type
nonparoxysmal AF) (1)
See page 1295
.
Before we assess the impact of this important study on
how we risk-stratify patients for AF ablation benefit and
improved outcomes, we need to consider the impact of these
findings on our understanding of what causes AF, why
ablation fails, and why the MS should matter at all.
Insights into the pathogenesis of AF: why should MS
matter? The cause of AF remains poorly understood.
Substrate abnormalities that promote re-entry were once
considered the only mechanism of AF (8), but with the
recent demonstration of “focal” sources of AF, a more
comprehensive hypothesis for AF origin is acknowledged.
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has not prevented the explosion in the past decade of AF
ablation procedures (9). However, not obtaining optimal suc-
cess is the rule rather than the exception with AF ablation, and
we now recognize that for future improvement, a better
understanding of the pathogenesis of AF is necessary. Mo-
hanty et al. (1) provide unique insights into AF pathogenesis
by exploring the relationship of AF with MS.
INFLAMMATION. Two of the independent factors predict-
ng AF recurrence after ablation were C-reactive protein
nd white blood cell count. Cause and effect with regard to
-reactive protein has been unclear, with 1 study showing
hat C-reactive protein levels decrease after successful abla-
ion, implying that inflammation is a result of the arrhyth-
ia. The present study (1), however, found that pre-
blation markers of inflammation predicted recurrence,
uggesting cause not only for AF but for ablation failure.
his finding highlights a conundrum with AF ablation. The
ore we ablate, the more likely we are to eliminate AF triggers
nd modify substrate, but the associated inflammatory response
ay be arrhythmogenic, at least in the short term.
HYPERTENSION. Hypertension, an integral component of
S, is a well-known risk factor for developing AF. Chronic
lood pressure elevation is associated with atrial myocyte
ypertrophy, myolysis, conduction abnormalities, and in-
reased AF, even without changes in refractoriness (10).
DIABETES MELLITUS (DM). DM and insulin resistance have
stablished adverse effects on myocardium and arterial stiffness.
direct electrophysiological consequence of DM is not estab-
ished (6,7). However, in 1 study, DM was an independent
redictor of very late recurrence after AF ablation (3,6,7).
OBESITY. A complex and multifactorial link between obe-
sity and AF likely exists. Elevated plasma volume, neuro-
hormonal activation, and electrical instability (11), along
with oxidative stress and inflammation, serve to increase the
likelihood of AF. In addition, noncardiac associations such
as autonomic dysfunction and sleep apnea (12,13) may
increase atrial arrhythmogenicity in obese patients.
MS: THE WHOLE IS MORE The propensity to create
tructural abnormalities and electrical instability for MS
ppears more than additive of what has been observed for its
ndividual components (7,14). This suggests that a common
nderlying condition that requires the multiple components
f MS increases AF likelihood. Two such candidate conditions
re diastolic dysfunction and increased left atrial size (6).
nsights into recurrence: why does ablation fail? Al-
hough earlier studies showed an association between the
ccurrence of MS and AF, Mohanty et al. (1) have shown
hat ablation fails more commonly when MS is present. For
blation success, both initiating triggers and arrhythmo-
enic substrate need to be addressed. In this study, the
xcess of recurrence of AF after ablation was exclusively
imited to the population with nonparoxysmal AF. In this
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April 3, 2012:1302–3 AF and Metabolic Syndromepopulation, it is likely that negative structural remodeling is
the key arrhythmogenic process. Given the extensive cellular
and whole atrial changes associated with the components of
MS, we learn from this study that atrial arrhythmogenic
substrate is a moving target. Because in most patients, MS
is an ongoing state, substrate changes possibly continue to
occur, and a 1-time ablation-based “substrate modification”
may be insufficient. It is also possible that we simply do not
yet know how to modify arrhythmogenic substrate (15).
However, in other similar recent studies relating MS to
ablation failure (14), paroxysmal AF had a higher rate of
recurrence in patients with MS. The differences between
these and the Mohanty et al. (1) reports are unclear, but in
the present study, there was an aggressive approach to
eliminate triggers (up to 30 g isoproterenol and non–
pulmonary vein trigger elimination). On the basis of this
assumption of difference, perhaps we learn that trigger
elimination, even if in a 1-time procedure, can be effective
despite an ongoing primary arrhythmia-provoking process.
Is there a way out? If what we have learned from this
informative study (1) is that substrate abnormalities may be
progressive and we do not have a uniformly effective method to
treat structural arrhythmogenic substrate in patients with AF,
can we hope for a true disease-modifying effect with ablation in
the future? If AF is simply a symptom of an underlying process
related to the components of MS and possibly diastolic
dysfunction, how can we address AF in a permanent fashion
without changing the underlying process? The paracardiac
autonomic nervous system lies in close physical proximity to
the pulmonary vein ostia and has been investigated as a
potential target for AF ablation (16,17). Present approaches
pioneered by Scherlag et al. (16) involve atrial ablation to target
these epicardial ganglia. However, the enhanced inflammatory
response with myocardial ablation along with proarrhythmic
macrore-entry may offset gains. Given the decreased incidence
of AF in denervated hearts after transplantation (18), perhaps
approaches similar to these need to be developed to render AF
less likely to recur regardless of an ongoing provocatory
substrate? Knowing that we cannot halt the underlying process,
can we make the atria immune to fibrillation?
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